Lilly-Camurus deal headlines slow week for partnerships: Deals Report

ASCO data stole the spotlight last week, as only a handful of biopharma companies announced deals, with very few disclosed financial terms. 

The largest partnership featured Eli Lilly and Co. (NYSE:LLY) engaging Camurus AB (SSE:CAMX) to use its FluidCrystal technology to develop long-acting formulations of up to four Lilly incretins. The upfront payment was not disclosed, but the Swedish biotech is eligible for up to $870 million in milestones and a mid-single-digit royalty. The specific Lilly products, also undisclosed, could include dual GIP and GLP-1 receptor agonists, triple GIP, glucagon and GLP-1 receptor agonists, and amylin receptor agonists. ...